DC
NKTR icon

Davenport & Co’s Nektar Therapeutics NKTR Stock Holding History

Davenport & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,780
Closed -$225K – 1055
2022
Q1 		$225K Sell
2,780
-13
-0.5% -$1.92K ﹤0.01% 967
2021
Q4 		$566K Buy
+2,793
New +$606K ﹤0.01% 721

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Davenport & Co's NKTR Position: Q2 2022 in Review

Davenport & Co sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 3,153 shares — an estimated $255K sold.

Davenport & Co first reported a position in NKTR in Q1 2019 and held it in 13 quarters. The position peaked at $1.45M in Q2 2020. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • Davenport & Co reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Davenport & Co sold 3,153 Nektar Therapeutics shares in Q2 2022, an estimated $255K.
  • Davenport & Co first reported a position in Nektar Therapeutics in Q1 2019 and held it in 13 quarters.
  • Davenport & Co's Nektar Therapeutics position peaked at $1.45M in Q2 2020.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Davenport & Co's 13F filing for Q2 2022, filed 18 Jul 2022.